Anti-cd8 alpha depleting antibodies
AssigneePolygon Therapeutics
InventorsTatiana MONSEUR, Mohamed ABOU ALI
Life of this patent
Estimating the term…
Abstract
Novel anti-CD8α (cluster of differentiation 8 alpha) antibodies and antigen-binding fragments thereof, a fusion protein including the anti-CD8α antibodies and antigen-binding fragments thereof, and a nucleic acid molecule encoding the anti-CD8α antibodies and antigen-binding fragments thereof. Also, pharmaceutical compositions including the anti-CD8α antibodies and antigen-binding fragments thereof. Further, methods using the anti-CD8α antibodies and antigen-binding fragments thereof for treating CD8-related diseases and in vitro methods in which CD8a-expressing cells are depleted in a sample or in which CD8α is detected or quantified in a sample.
Claims12
An isolated anti-CD8α antibody, or antigen-binding fragment thereof, wherein:
- a. the variable region of the heavy chain (VH) of said isolated anti-CD8α antibody, or antigen-binding fragment thereof, comprises the three following CDRs:
- VH-CDR1:
- (SEQ ID NO:
- 6)
- NNAMN;
- VH-CDR2:
- (SEQ ID NO:
- 7)
- DISGSSRYIGYADFVKG;
- and/or
- -VH-CDR3:
- (SEQ ID NO:
- 8)
- SSNYYDYNADAMDV.
- and
- b. the variable region of the light chain (VL) of said isolated anti-CD8α antibody, or antigen-binding fragment thereof, comprises the three following CDRs:
- VL-CDR1:
- (SEQ ID NO:
- 9)
- AGTSSDVGGNSYVS;
- VL-CDR2:
- (SEQ ID NO:
- 10)
- SDSSRPS;
- and/or
- VL-CDR3:
- (SEQ ID NO:
- 11)
- SSYTQYSTRV.
Dependencies are inferred from the claim text.